Dr. Reddy’s Laboratories have received final approval from the US FDA and is launching
buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of suboxone (buprenorphine and naloxone) sublingual film. In treating adults with opioid dependence/addiction, buprenorphine helps suppress withdrawal symptoms caused by discontinuation of opioid drug use, and naloxone reverses and blocks the effect of opioids. This combination of medications is used as part of a complete treatment program including prescription monitoring, counseling, and psychosocial support.